The Manufacturers Life Insurance Company lifted its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 27.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,528 shares of the company’s stock after buying an additional 6,756 shares during the period. The Manufacturers Life Insurance Company’s holdings in Sanofi were worth $1,530,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Boston Partners boosted its position in Sanofi by 0.3% in the first quarter. Boston Partners now owns 13,066,403 shares of the company’s stock worth $635,280,000 after purchasing an additional 33,657 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after buying an additional 1,370,232 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC lifted its position in shares of Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after buying an additional 3,164,092 shares in the last quarter. Mondrian Investment Partners LTD lifted its position in shares of Sanofi by 43.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after buying an additional 1,190,141 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in shares of Sanofi by 8.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after buying an additional 246,224 shares in the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.
Sanofi Stock Performance
NASDAQ:SNY opened at $54.77 on Friday. The stock’s fifty day moving average is $55.77 and its 200 day moving average is $51.29. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97. The firm has a market capitalization of $138.72 billion, a PE ratio of 27.52, a PEG ratio of 1.56 and a beta of 0.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on the company. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Citigroup raised Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Argus lifted their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $57.50.
Read Our Latest Research Report on Sanofi
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Recommended Stories
- Five stocks we like better than Sanofi
- Golden Cross Stocks: Pattern, Examples and Charts
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- What is a Low P/E Ratio and What Does it Tell Investors?
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- Upcoming IPO Stock Lockup Period, Explained
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.